These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23612993)

  • 21. Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
    van der Ryst E; Heera J; Demarest J; Knirsch C
    Ann N Y Acad Sci; 2015 Jun; 1346(1):7-17. PubMed ID: 25962411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers.
    Doncel GF; Clark MR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S10-8. PubMed ID: 21109063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silent, but deadly--eliminating reservoirs of latent HIV.
    Kay MS
    Trends Biotechnol; 2003 Oct; 21(10):420-3. PubMed ID: 14512225
    [No Abstract]   [Full Text] [Related]  

  • 24. Developing regulatory strategy for microbicides.
    Nardi R; Arterburn L; Carlton L
    Curr Top Microbiol Immunol; 2014; 383():137-52. PubMed ID: 24126799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Resistance screening].
    Sierra S; Lengauer T; Kaiser R
    MMW Fortschr Med; 2009 Apr; 151(18):72, 74-5. PubMed ID: 19769083
    [No Abstract]   [Full Text] [Related]  

  • 27. Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
    Parienti JJ; Peytavin G
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):495-503. PubMed ID: 21417819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Integrase inhibition].
    Bogner JR
    MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
    [No Abstract]   [Full Text] [Related]  

  • 29. [Approval of a new nucleoside. Component of complete once daily regimen].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
    [No Abstract]   [Full Text] [Related]  

  • 30. Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges.
    Lenz JC; Rockstroh JK
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1139-50. PubMed ID: 20712521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interscience Conference on Antimicrobial Agents and Chemotherapy--47th Annual Meeting. HIV/AIDS and other retroviruses. 17-20 September 2007, Chicago, IL, USA.
    Cleverley J; Din S
    IDrugs; 2007 Nov; 10(11):759-61. PubMed ID: 17968751
    [No Abstract]   [Full Text] [Related]  

  • 32. The future of HIV prevention: prospects for an effective anti-HIV microbicide.
    Nuttall J; Romano J; Douville K; Galbreath C; Nel A; Heyward W; Mitchnick M; Walker S; Rosenberg Z
    Infect Dis Clin North Am; 2007 Mar; 21(1):219-39, x. PubMed ID: 17502237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design issues in initial HIV-treatment trials: focus on ACTG A5095.
    Ribaudo HJ; Kuritzkes DR; Schackman BR; Acosta EP; Shikuma CM; Gulick RM
    Antivir Ther; 2006; 11(6):751-60. PubMed ID: 17310819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The need for novel targets and approaches to HIV therapy.
    Martinez LJ
    Res Initiat Treat Action; 2002; 8(1):23-5. PubMed ID: 12489523
    [No Abstract]   [Full Text] [Related]  

  • 35. [The natural history of of the antiretrovirals: the continuum of their evaluation].
    Guerra Romero L; Stanley K; Parras Vázquez F
    Med Clin (Barc); 1999; 112 Suppl 1():59-66. PubMed ID: 10618801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamivudine for the treatment of HIV.
    Kumar PN; Patel P
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):105-14. PubMed ID: 20001611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Principles of HIV resistance testing and overview of assay performance characteristics.
    Richman DD
    Antivir Ther; 2000 Mar; 5(1):27-31. PubMed ID: 10846590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Boone LR
    Curr Opin Investig Drugs; 2006 Feb; 7(2):128-35. PubMed ID: 16499282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances on anti-HIV vaginal delivery systems development.
    Antimisiaris SG; Mourtas S
    Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.